Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Steven Dowdy
University of California, San Diego, Department: Other Basic Sciences
Should you be removed from our database? Contact us at [email protected]. Read more below.
Solstice Biologics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Dowdy is a founder and on the Board of Directors of Solstice Biologics (Solstice). He holds (b)(4) equity in the company valued between (b)(4) and receives compensation for consulting. The consulting ended November 2016. The company is developing the next generation of RNAi triggers, called siRNNs that directly address both the delivery and stability problems of RNAi therapeutics. The project will test the ability of a self-delivering, next generation siRNN RNAi therapeutic to treat Adenovirus conjunctivitis in preclinical rabbit models.
Treating Adenovirus Conjunctivitis with Next-Gen siRNN RNAi Prodrugs
NARRATIVE Adenovirus conjunctivitis is currently an untreatable form of pink eye characterized by rapid and consequential infection of the contralateral eye, other family members and lost days of school/work resulting in a significant health and economic burden. Topical RNAi therapeutics have great potential to target Adenovirus specific genes to stop viral infection with a single dose that lasts for greater than one month. This project will test the ability of a self-delivering, next-generation siRNN RNAi therapeutic to treat Adenovirus conjunctivitis in preclinical rabbit models.
Filed on June 12, 2017.
Tell us what you know about Steven Dowdy's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Steven Dowdy filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Steven Dowdy | University of California, San Diego | Conflict of Interest | Solstice Biologics | $40,000 - $59,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.